 YONKERS, N.Y., June 17, 2021 GLOBE NEWSWIRE -- ContraFect Corporation Nasdaq:CFRX, a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Gary Woodnutt, Ph.D. has been appointed as Senior Vice President of Translational Sciences and Preclinical Development. Dr. Woodnutt will oversee the scientific strategy for the Companys early stage assets and the performance of the extensive translational programs required to proceed into clinical trials. He will have a pivotal role in the regulatory strategy for the preclinical aspects of Investigational New Drug IND applications as well as the potential BLA for exebacase. Dr. Woodnutt has over 30 years of experience leading the discovery and development of innovative therapies ranging from antibiotics to novel protein-based therapeutics. 